>
Adaptimmune Therapeutics logo

ADAP - Adaptimmune Therapeutics Share Price

$4.85 0.1  2.8%

Last Trade - 6:58pm

Sector
Healthcare
Size
Mid Cap
Market Cap £525.4m
Enterprise Value £261.2m
Revenue £2.84m
Position in Universe 3111th / 6852
Bullish
Bearish
Unlock ADAP Revenue
Momentum
Relative Strength (%)
1m -13.6%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -64.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
8.98 14.2 37.8 59.5 1.12 3.96 3.80 13.8 -15.1%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020,Adaptimmune Therapeutics PLC - ADR revenues increased from$1.1M to $4M. Net loss decreased 5% to $130.1M. Revenuesreflect an increase in demand for the Company's productsand services due to favorable market conditions. Lower netloss reflects Labor & Related Expenses in R&D decrease of60% to $25.4M (expense), Stock-based Compensation in SGAdecrease of 17% to $6M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ADAP
Graphical History

Revenue

ADAP Revenue Unlock ADAP Revenue

Net Income

ADAP Net Income Unlock ADAP Revenue

Normalised EPS

ADAP Normalised EPS Unlock ADAP Revenue

PE Ratio Range

ADAP PE Ratio Range Unlock ADAP Revenue

Dividend Yield Range

ADAP Dividend Yield Range Unlock ADAP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ADAP EPS Forecasts Unlock ADAP Revenue
Profile Summary

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its SPEAR T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (TCRs) against those targets, and produce therapeutic candidates (SPEAR T-cells) for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company’s product pipeline includes ADP-A2M4, ADP-A2M4CD8, ADP-A2AFP and ADP-A2M10. Its ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy is directed to a member of the MAGE family of cancer testis antigen expressed in a number of solid tumor cell types.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated December 3, 2014
Public Since May 6, 2015
No. of Shareholders: 27
No. of Employees: 462
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 155,137,945
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ADAP Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ADAP
Upcoming Events for ADAP
Frequently Asked Questions for Adaptimmune Therapeutics
What is the Adaptimmune Therapeutics share price?

As of 6:58pm, shares in Adaptimmune Therapeutics are trading at $4.85, giving the company a market capitalisation of £525.4m. This share price information is delayed by 15 minutes.

How has the Adaptimmune Therapeutics share price performed this year?

Shares in Adaptimmune Therapeutics are currently trading at $4.85 and the price has moved by 31.84% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Adaptimmune Therapeutics price has moved by -13.34% over the past year.

What are the analyst and broker recommendations for Adaptimmune Therapeutics?

Of the analysts with advisory recommendations for Adaptimmune Therapeutics, there are there are currently 1 "buy" , 4 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Adaptimmune Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Adaptimmune Therapeutics next release its financial results?

Adaptimmune Therapeutics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Adaptimmune Therapeutics dividend yield?

Adaptimmune Therapeutics does not currently pay a dividend.

Does Adaptimmune Therapeutics pay a dividend?

Adaptimmune Therapeutics does not currently pay a dividend.

When does Adaptimmune Therapeutics next pay dividends?

Adaptimmune Therapeutics does not currently pay a dividend.

How do I buy Adaptimmune Therapeutics shares?

To buy shares in Adaptimmune Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Adaptimmune Therapeutics?

Shares in Adaptimmune Therapeutics are currently trading at $4.85, giving the company a market capitalisation of £525.4m.

Where are Adaptimmune Therapeutics shares listed? Where are Adaptimmune Therapeutics shares listed?

Here are the trading details for Adaptimmune Therapeutics:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ADAP
What kind of share is Adaptimmune Therapeutics?

Based on an overall assessment of its quality, value and momentum, Adaptimmune Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Adaptimmune Therapeutics share price forecast 2021?

Shares in Adaptimmune Therapeutics are currently priced at $4.85. At that level they are trading at 1.34% discount to the analyst consensus target price of 0.00.

Analysts covering Adaptimmune Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -0.996 for the next financial year.

How can I tell whether the Adaptimmune Therapeutics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adaptimmune Therapeutics. Over the past six months, the relative strength of its shares against the market has been -8.63%. At the current price of $4.85, shares in Adaptimmune Therapeutics are trading at -27.56% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Adaptimmune Therapeutics PE Ratio?

We were not able to find PE ratio data for Adaptimmune Therapeutics.

Who are the key directors of Adaptimmune Therapeutics?

Adaptimmune Therapeutics's management team is headed by:

James Noble - NED
Helen Tayton-Martin - OTH
Adrian Rawcliffe - CEO
Lawrence Alleva - NID
Ali Behbahani - NID
David Mott - NEC
Barbara Duncan - NID
William Bertrand - COO
John Lunger - OTH
Elliot Norry - SVP
Gavin Wood - CFO
Who are the major shareholders of Adaptimmune Therapeutics?

Here are the top five shareholders of Adaptimmune Therapeutics based on the size of their shareholding:

Matrix Capital Management Company, LP Investment Advisor/Hedge Fund
Percentage owned: 25.07% (39.0m shares)
New Enterprise Associates (NEA) Venture Capital
Percentage owned: 10.99% (17.1m shares)
Baillie Gifford & Co. Investment Advisor
Percentage owned: 6.66% (10.4m shares)
Baker Bros. Advisors LP Hedge Fund
Percentage owned: 6.32% (9.83m shares)
American Funds SMALLCAP World Fund Mutual Fund
Percentage owned: 6% (9.32m shares)
Similar to ADAP
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.